

Breast Cancer

	Endocrine Therapy	ER/PR-POSITIVE HER2 NEGATIVE	HER2 POSITIVE	"TRIPLE NEGATIVE" EP/PR -NEGATIVE HER2-NEGATIVE	
Pre-Op Therapy	No Trial Currently Available	IRB#6256-ISP2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular			
Surgical Therapy	IRB#9340- Phase II breast conservation surgery and radiation therapy study				
Adjuvant Therapy	No Trial Currently Available		<p>IRB#15366 Phase 2 Study of ONT-380 vs. Placebo with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (Applies to Adjuvant, 1st line and beyond HER2 + MBC therapy)</p>	<p>IRB# 17461 S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and</p>	
1st line MBC Therapy	No Trial Currently Available	<p>IRB#11351 Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced</p>		<p>IRB # 17016 COMPLEEMENT-1: An open -label Phase 3 to evaluate safety and efficacy of ribociclib in compination with</p>	<p>IRB#11351 Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced Unresectable Breast Cancer</p>
2nd line MBC Therapy		<p>IRB#16379 C31006: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor</p>		No Trial Currently Available	
3rd line MBC Therapy		No Trial Currently Available		No Trial Currently Available	
"Heavily Pre-treated" Therapy		No Trial Currently Available		No Trial Currently Available	

Key

- Open for Enrollment
- In Development
- Enrollment on Hold